The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Real-world use of fedratinib in patients with MF who have failed on ruxolitinib
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, briefly comments on the use of fedratinib in the real-world setting in patients with myelofibrosis (MF) who have experienced treatment failure with ruxolitinib. This agent appeared to improve splenomegaly and disease symptoms in this patient population in the real-world setting, confirming findings of clinical trials such as JAKARTA2 (NCT01523171). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, GlaxoSmithKline, Kartos, Novartis, PharmaEssentia, Sierra Oncology
Research Funding: Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation, Kratos Pharmaceuticals
